Milestone Pharmaceuticals (MIST) Retained Earnings (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Retained Earnings came in at -$456.7 million in Q1 2026, down 17.61% YoY from -$554.3 million in Q1 2025, and down 812.39% on a QoQ basis from $64.1 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Retained Earnings (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Retained Earnings data on file, last reported at -$456.7 million in Q1 2026.
- Quarterly Retained Earnings fell 17.61% year-over-year to -$456.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$456.7 million (down 17.61% YoY) and the FY2025 annual result came in at $64.1 million, up 117.44% from the prior year.
- Retained Earnings declined to -$456.7 million in Q1 2026, from $64.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $64.1 million in Q4 2025 to a low of -$456.7 million in Q1 2026.
- A 5-year average of -$152.0 million and a median of $17.8 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 2109.33% — and 2025, when it jumped 117.44%.
- Tracing MIST's Retained Earnings over 5 years: stood at $24.4 million in 2022, then jumped by 38.45% to $33.8 million in 2023, then plunged by 1186.32% to -$367.5 million in 2024, then surged by 117.44% to $64.1 million in 2025, then plunged by 812.39% to -$456.7 million in 2026.
- The last three Retained Earnings figures came in at -$456.7 million (Q1 2026), $64.1 million (Q4 2025), and -$413.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | -485.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -485.30 Mn |
| Mar 31, 2026 | -456.67 Mn |
| Dec 31, 2025 | 64.10 Mn |
| Sep 30, 2025 | -413.20 Mn |
| Jun 30, 2025 | -401.27 Mn |
| Mar 31, 2025 | -388.30 Mn |
| Dec 31, 2024 | -367.55 Mn |
| Sep 30, 2024 | 38.11 Mn |
| Jun 30, 2024 | 36.71 Mn |
| Mar 31, 2024 | -336.40 Mn |
| Dec 31, 2023 | 33.83 Mn |
| Sep 30, 2023 | 31.96 Mn |
| Jun 30, 2023 | 29.11 Mn |
| Mar 31, 2023 | -281.30 Mn |
| Dec 31, 2022 | 24.44 Mn |
| Sep 30, 2022 | 22.44 Mn |
| Jun 30, 2022 | -237.00 Mn |
| Mar 31, 2022 | 17.79 Mn |
| Dec 31, 2021 | 15.71 Mn |
| Sep 30, 2021 | 13.79 Mn |